Older Adults' Attitudes Towards Stopping Aspirin

April 28, 2026 updated by: Sarah Vordenberg, University of Michigan
This online, survey-based experiment will include 2,400 adults who are 65 years and older (n=1,200 each from the United States and Australia). Each participant will be asked to share their opinions on a hypothetical patient scenario developed by our multidisciplinary team. This work is expected to significantly contribute to the understanding of how older adults make decisions about deprescribing medications. The long-term goal is to enhance communication between older adults and clinicians so that medication regimens are optimized and align with care preferences. These results will directly inform future research on the impact of communication choices in clinical practice.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

2819

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Michigan
      • Ann Arbor, Michigan, United States, 48109
        • University of Michigan

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Reside in Australia or the United States
  • 65 years and older

Exclusion Criteria:

  • Unable to read survey written in English

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Source of recommendation - Physician
Participants read a hypothetical scenario where a doctor recommends stopping aspirin.
Other: Additional harm information
Participants received additional information about the harm of continuing aspirin.
Other: Less information
Participants will receive less information about the risk of harms of continuing aspirin.
Experimental: Source of recommendation - Pharmacist
Participants read a hypothetical scenario where a pharmacist recommends stopping aspirin.
Other: Additional harm information
Participants received additional information about the harm of continuing aspirin.
Other: Less information
Participants will receive less information about the risk of harms of continuing aspirin.
Experimental: Source of information - AI
Participants read a hypothetical scenario where artificial intelligence is used to recommend stopping aspirin.
Other: Additional harm information
Participants received additional information about the harm of continuing aspirin.
Other: Less information
Participants will receive less information about the risk of harms of continuing aspirin.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
"How safe do you think it would be to continue taking aspirin?" measured on a 6-point Likert scale
Time Frame: Day 1
Day 1
"How helpful do you think it would be to continue taking aspirin?" measured on a 6-point Likert scale
Time Frame: Day 1
Day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Michigan

Collaborators

University of Sydney

Investigators

  • Principal Investigator: Sarah Vordenberg, PharmD, MPH, University of Michigan

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 10, 2025

Primary Completion (Actual)

November 30, 2025

Study Completion (Actual)

November 30, 2025

Study Registration Dates

First Submitted

November 13, 2025

First Submitted That Met QC Criteria

December 11, 2025

First Posted (Actual)

December 26, 2025

Study Record Updates

Last Update Posted (Actual)

April 29, 2026

Last Update Submitted That Met QC Criteria

April 28, 2026

Last Verified

November 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HUM00280646

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Medication Overuse

Clinical Trials on Additional harm information

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe